Antidiabetic activity of aqueous extract of leaves of cnestis ferruginea vahl ex DC. (Connaraceae) on alloxan-diabetic induced mice.

2021 ◽  
Vol 4 (1) ◽  
pp. 1-6
Author(s):  
Emile K. Begbin ◽  
Edwige A. Odoh ◽  
Ernest N. Zougrou ◽  
Landry Claude A. Kablan ◽  
Diéneba Kone-Bamba ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Blood Sugar ◽  
Aqueous Extract ◽  
White Blood Cells ◽  
Hdl Cholesterol ◽  
Treated Group ◽  
Antidiabetic Activity ◽  
Metformin Group ◽  
Hematological And Biochemical Parameters ◽  
Group B

Abstract Background: Cnestis ferruginea is a plant species widely used in the traditional african medicine to treat diabetes mellitus. The present study aimed to evaluate the antidiabetic activities of the aqueous extract of the leaves of Cnestis ferruginea (AECF) in diabetic mice. Methods: The mice were grouped into five groups of five animals per group: Group A was not induced with alloxan, Group B animals were induced but not treated, Group C animals were treated with 500 mg / kg of BW of metformin, Group D and E animals were treated with 100, 200 mg/kg BW of AECF respectively. The extracts were administered to the animals orally for 14 days. Fasting blood sugar was measured by a glucometer. Serum concentrations of hematological and biochemical parameters were measured by standard methods. Results: The animals administered with 100 and 200 mg/Kg B.W of extract showed highly significant decrease (P ˂ 0.0001) in blood sugar level compared to the untreated animals. The 100 mg / kg BW dose of AECF produce low significant decrease (P <0.05) of total cholesterol, HDL Cholesterol, AST, ALT, urea, levels of white blood cells, platelets, hematocrit. The 200 mg / kg BW dose of AECF produce in addition significant decrease (P <0.01) of AST and urea. Conclusion: The 200 mg / kg dose of BW of AECF had a greater antidiabetic activity than the dose of 100 mg / kg BW. Keywords: Cnestis ferruginea; antidiabetic activity; alloxan; diabetes mellitus.

Anti-Diabetic Effect of a Flavonoid and Sitosterol - Rich Aqueous Extract ofPleurotus tuberregiumSclerotia in Alloxan-Induced Diabetic Rabbits

2019 ◽  
Vol 19 (8) ◽  
pp. 1148-1156 ◽  
Author(s):  
Ifeanacho Mercy Onuekwuzu ◽  
Ikewuchi Catherine Chidinma ◽  
Ikewuchi Jude Chigozie
Keyword(s):  
Diabetes Mellitus ◽  
Blood Glucose ◽  
Aqueous Extract ◽  
Risk Index ◽  
Fasting Blood Glucose ◽  
Hdl Cholesterol ◽  
The Body ◽  
Atherogenic Index ◽  
Atherogenic Indices ◽  
Diabetic Rabbits

Objective:Traditionally prepared infusions and decoctions are commonly used in the management of diabetes mellitus, in southern Nigeria; one of such is the aqueous extract of the sclerotia of Pleurotus tuberregium (“usu” milk). In this study, the effects of the extract on the body weights, tissue/ organ weights, fasting blood glucose, blood/plasma lipid profiles and atherogenic indices were investigated in normal and alloxan-induced diabetic rabbits.Methods:Diabetes mellitus was induced by the injection of alloxan (120 mg/kg body weight) via the marginal ear vein. The extract was administered orally at 100, 200 and 300 mg/kg to normal and diabetic rabbits; while metformin was administered at 50 mg/kg. The crude extract was analyzed by gas chromatography, coupled to flame ionization detector.Results:Thirty-one known flavonoids were detected, consisting mainly of isoquercetin (28.5%), luteolin (24.3%), quercetin (18.8%) and kaempferol (11.3%). Sitosterol (82.0%) and stigmasterol (12.5%) were the most abundant of the seven phytosterols detected. Compared to the diabetic control, the treatment significantly (p<0.05) lowered the weights of the kidney and liver, as well as the levels of blood glucose and triglyceride, plasma VLDL, LDL and non-HDL cholesterol, atherogenic index of plasma, cardiac risk ratio, atherogenic coefficient and Castelli’s risk index II. It, however, significantly (p<0.05) increased plasma HDL cholesterol, without significantly affecting blood total cholesterol levels.Conclusion:This study showed that the extract was hypoglycemic, and improved lipid profile and atherogenic indices, thus highlighting its cardioprotective potential, thereby supporting its use in the management of diabetes mellitus.

scholarly journals Anti-hyperglycemic Effects of Diacerein in Alloxan-Induced Diabetes Mellitus in Wistar Albino Rats

2020 ◽  
pp. 107-113
Author(s):  
Arsalan Uqaili ◽  
Samia Siddiqui ◽  
Roomi Aijaz ◽  
Yar Muhammad Nizammani ◽  
Navaid Kazi ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Body Weight ◽  
Blood Glucose ◽  
Treated Group ◽  
Diabetic Control ◽  
Diabetic Rats ◽  
Control Group ◽  
Albino Rats ◽  
Group B ◽  
Group D

Objective: To determine the anti-hyperglycemic effects of interleukin-1 inhibitor (diacerein) in alloxan induced diabetic albino wistar rats. This experimental study was performed at the Department of Animal Husbandry and Veterinary Sciences, Sindh Agriculture University, Tando Jam within 6 months from April 2016 to September 2016. Total of 160 adult Albino Wistar Rats having an average of 200 to 300 grams body weights were selected. Animals were categorized into 4 groups as; Group A (n=15): Control rats – receive 0.9% normal saline as placebo Experimental Groups Group B (n=15): Experimental Control (Diabetic rats) - Alloxan50 mg/kg body weight intraperitoneal. Group C (n=15): Diabetic rats + Diacerein (30 mg/kg/day) orally daily. Group D (n=15): Diabetic rats + Diacerein (50 mg/kg/day) orally daily. Animals were kept and treated as per the NIH Guideline for Use and Care of Laboratory Animals. Diabetes mellitus was induced via a single intraperitoneal injection of 50 milligram/kg alloxan monohydrated dissolved in aseptic 0.9% saline. After 72 hours, blood specimens were taken from the caudal vein of the rats and glucose level>200 mg/dL was taken as diabetes. Experimental rats were given diacerein approximately 30 and 50 mg orally for 6 weeks. At the completion of experiment the body weight was measured of each animal by electronic measuring balance and blood sample was taken from each animal of all groups to assess the blood glucose level and HbA1c level. Data were recorded via self-made proforma and analysis was done by using SPSS version 20. Results: Average body weight of Diabetic control (Group B) was 193.33±22.50 grams, which was lower in contrast to Diacerein treated group C 202.47±25.70 grams and significantly lower as compared to Diacerein treated group D as  212.6±23.43 grams. A significant increase in blood glucose levels 182.07±10.63 mg/dl was noted in the Diabetic control (Group B) compared to Diacerein treated group C (110.13± 8.54 mg/dl) and group D (85.87±8.41 mg/dl) (P=0.001). HbA1c was markedly raised in the Group B- diabetic controls, while diacerein treated diabetic rats (groups C and D) showed a significant decrease in HbA1c (P=0.001). Conclusion: It was concluded that Diacerein achieves the Euglycemic state by reducing the levels of blood glucose and glycated hemoglobin (HbA1c) in Alloxan-Induced diabetes mellitus in Wistar Albino Rats.

scholarly journals Oral Hypoglycemic Glibenclamide: Can it be a Substitute to Insulin in the Management of Gestational Diabetes Mellitus? A Comparative Study

2012 ◽  
Vol 4 (1) ◽  
pp. 28-31 ◽  
Author(s):  
Partha Mukhopadhyay ◽  
Tara Sankar Bag ◽  
Amit Kyal ◽  
Dipta Prasun Saha ◽  
Noori Khalid
Keyword(s):  
Diabetes Mellitus ◽  
Blood Glucose ◽  
Birth Weight ◽  
Glycemic Control ◽  
Gestational Diabetes ◽  
Gestational Diabetes Mellitus ◽  
Comparative Study ◽  
Blood Sugar ◽  
Group A ◽  
Group B

ABSTRACT Introduction Gestational diabetes is a common medical disorder in pregnancy. So long, it has been usually treated by insulin. Now it has been found that oral glibenclamide can be used instead of insulin with similar glycemic control and without any adverse maternal and fetal effect. Methods A comparative study between oral glibenclamide and insulin for the management of gestational diabetes mellitus (GDM) was conducted. It was a prospective randomized study and patients attending the antenatal clinic were screened with 75 gm oral glucose between 20 to 28 weeks and GDM was diagnosed based on WHO criteria of 2 hours blood glucose ≥140 mg/dl. Women with gestational diabetes were given medical nutritional therapy (MNT) for 2 weeks. Out of this, 60 women did not achieve the target blood glucose. The goal of treatment was maintenance of mean plasma glucose (MPG) of about 105 mg%. For this the fasting plasma glucose should be around 90 mg/dl and postprandial peaks around 120 mg/dl. Patients were randomly assigned to receive glibenclamide (group A, n = 30) or insulin (group B, n = 30). In group A, glibenclamide was given 2.5 mg orally in morning and doses were increased weekly by 2.5 mg up to a maximum of 20 mg and doses >7.5 mg were given in two divided doses. In group B, insulin 0.7 units per kilogram of body weight at admission was given subcutaneously three times daily and increased weekly as necessary. Self monitoring of blood glucose with glucometer was done. Blood glucose was also measured from the laboratory every week. Glycosylated hemoglobin (HbA1c) was measured before initiation of therapy and repeated in the third trimester before confinement. Terminations of pregnancy in both the groups were done between 37 and 38 weeks. The infant birth weight, blood glucose and serum bilirubin were also recorded in all cases. Results The present study showed that the two groups had similar glycemic status (fasting blood sugar in group A was 103.5 ± 14.62 mg/dl and postprandial blood sugar was 184.1 ± 20.46 mg/dl whereas in group B it was109.3 ± 19.63 mg/dl and 194.3 ± 18.47mg/dl) at the time of entry into the study. The two groups also showed similar levels of glycemic control just before confinement (fasting blood sugar in group A was 88.23 ± 6.55 mg/ dl and postprandial blood sugar was 122.7 ± 10.3 mg/dl whereas in group B it was 88.17 ± mg/dl and 128 ± 12.38 mg/dl) and there was no significant statistical difference in the two groups (p > 0.05). The perinatal outcomes in both the groups were also nearly same. There was no significant difference in birth weight, blood sugar level of neonates and complications between the two groups. There was no case of macrosomia in the two groups and the number of infants large for gestational age (LGA) was four in group A and two in group B. Hypoglycemia in newborn was slightly higher in the group A compared to group B (4 and 3 respectively). Conclusion From our study, it is evident that the use of oral agents is a pragmatic alternative to insulin therapy in cases of gestational diabetes because of similar glycemic control, ease of administration and better patient compliance due to noninvasive treatment. How to cite this article Mukhopadhyay P, Bag TS, Kyal A, Saha DP, Khalid N. Oral Hypoglycemic Glibenclamide: Can it be a Substitute to Insulin in the Management of Gestational Diabetes Mellitus? A Comparative Study. J South Asian Feder Obst Gynae 2012;4(1):28-31.

scholarly journals Antidiabetic Effects of the Ethanolic Root Extract ofUvaria chamaeP. Beauv (Annonaceae) in Alloxan-Induced Diabetic Rats: A Potential Alternative Treatment for Diabetes Mellitus

2018 ◽  
Vol 2018 ◽  
pp. 1-13
Author(s):  
Jonathan Emeka Emordi ◽  
Esther Oluwatoyin Agbaje ◽  
Ibrahim Adekunle Oreagba ◽  
Osede Ignis Iribhogbe
Keyword(s):  
Diabetes Mellitus ◽  
Alternative Treatment ◽  
Pancreatic Beta Cells ◽  
Hematological Parameters ◽  
Hdl Cholesterol ◽  
Diabetic Rats ◽  
Antidiabetic Activity ◽  
Root Extract ◽  
Acacia Senegal ◽  
Cholesterol Levels

Diabetes mellitus has been a menace to mankind from time immemorial. However, a natural product such asU. chamaeP. Beauv (Annonaceae) offers alternative treatment for diabetes mellitus. The study aimed at evaluating antidiabetic activity of the ethanolic root extract ofU. chamaein alloxan-induced diabetic rats. Diabetes was induced in Sprague Dawley rats after overnight fast with 150 mg/kg alloxan intraperitoneally. After 72 h, those with plasma glucose levels >200 mg/dl were classified as diabetic. Five diabetic rats in each group were treated daily for 14 days orally with 100, 250, and 400 mg/kg of the extract, glibenclamide (71 µg/kg) and pioglitazone (429 µg/kg), respectively, while another group was untreated. Control received 0.5 ml ofAcacia senegal. Effects of extract on glucose, other biochemical, and hematological parameters were evaluated.α-amylase andα-glucosidase inhibitory activities of extract and its fractions were also evaluated. Percentage inhibition and IC50values were determined. Diabetic control was achieved on the 7th day of the study with 100, 250, and 400 mg/kg of the extract showing glucose reduction of 72.14%, 78.75%, and 87.71%, respectively. The HDL-cholesterol levels of diabetic rats treated with extracts were significantly increased. Extract and its fractions causedα-amylase andα-glucosidase inhibition. Histologically, pancreas of diabetic rats treated with extract showed regenerated islet cells which were not seen in rats treated with glibenclamide and pioglitazone. This study showed thatU. chamaehas antidiabetic activity which may be throughα-amylase andα-glucosidase inhibition and regeneration of pancreatic beta cells. Also, it may reduce the risk of cardiovascular disease by increasing HDL-cholesterol levels.

scholarly journals Effects ofSalvadora persicaExtract on the Hematological and Biochemical Alterations against Immobilization-Induced Rats

Scientifica ◽  
2015 ◽  
Vol 2015 ◽  
pp. 1-5 ◽  
Author(s):  
Kholoud S. Ramadan ◽  
Salha A. Alshamrani
Keyword(s):  
Biochemical Parameters ◽  
Hematological Parameters ◽  
Hdl Cholesterol ◽  
Treated Group ◽  
Control Group ◽  
Serum Samples ◽  
Salvadora Persica ◽  
Biochemical Alterations ◽  
Hematological And Biochemical Parameters

A total of 24 rats were divided into 4 groups: control, stress, extract alone, and stress + extract (n=6each), for total 21 days of treatment. The immobilization stress was induced in rats by putting them in 20 cm × 7 cm plastic tubes for 2 h/day for 21 days. Rats were postorally treated withSalvadora persicaat a dose of 900 mg/kg body weight via intragastric intubations. At the end of the test period, hematological and biochemical parameters were determined in blood and serum samples with determination of vital organs weights. The vital organ weights were not significantly affected in stressed rats as compared to control rats. Compared to the control group, the stress treated group showed significances in several hematological parameters, including decreases in WBC, RBC, and PLT counts. Furthermore, in comparison to the control group, the stress group showed significantly increased blood glucose, serum total cholesterol, LDL-cholesterol, and triacylglycerols levels and decreased HDL-cholesterol level. The hematological and biochemical parameters in the stress + extract treated group were approximately similar to control group. The SP extract restored the changes observed following stress treatment.

scholarly journals The therapeutic effectiveness of sitagliptin with niacin and chromium picolinate on glycosylated hemoglobin in type 2 diabetes mellitus patients

2018 ◽  
Vol 5 (8) ◽  
pp. 2610-2619
Author(s):  
Fauzia Karim ◽  
Komal Najam ◽  
Ali Sharif ◽  
Lubna Shakir ◽  
Sana Ajmal ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Blood Sugar ◽  
Controlled Trial ◽  
Statistical Significance ◽  
Glycosylated Hemoglobin ◽  
Chromium Picolinate ◽  
Group B

Purpose: The purpose of this study was to evaluate the effectiveness of niacin (B3) on glycosylated hemoglobin (HbA1c), alone and as adjunct therapy, with chromium picolinate (CrPlt) and sitagliptin. In the present study, we have evaluated the effects of niacin and chromium picolinate supplementation with sitagliptin in Type 2 diabetes mellitus (T2DM) patients. Methods: A randomized controlled trial was conducted on 600 patients suffering from T2DM from four different hospitals in Lahore, Punjab, Pakistan; patients were divided into three groups (n=200 per group). Group A was given sitagliptin (100 mg), Group B received niacin (14 mg/d) along with sitagliptin, and Group C received chromium picolinate (200 mcg/d) and niacin (14 mg/d) along with sitagliptin, for a duration of 6 months. Analysis of variance (ANOVA) was used to compare the efficacy of all treatment groups, and statistical significance was set at p≤0.05. Results: The data indicated that all defined therapies have a significant influence with respect to fasting blood sugar (FBS) (p<0.0001), random blood sugar (RBS) (p<0.0001) and glycosylated hemoglobin (p<0.0001). Conclusion: Our study demonstrated that low doses of niacin and chromium picolinate supplementation with sitagliptin helps in maintaining glycemic control in patients with T2DM, and provides the best treatment option among those considered.

scholarly journals ANTI-HYPERGLYCEMIC EFFECT OF KUNDRU (COCCINIA INDICA) ON PATIENTS OF DIABETES MELLITUS TYPE-2

2020 ◽  
pp. 29-35
Author(s):  
Mohd Junaid ◽  
Bhavna Singh ◽  
Sahana vats ◽  
Sanandan Thapliyal ◽  
Shalini Thapliyal
Keyword(s):  
Diabetes Mellitus ◽  
Blood Sugar ◽  
Diabetes Mellitus Type 2 ◽  
Blood Sugar Level ◽  
Treated Group ◽  
Diabetes Mellitus Type ◽  
P Value ◽  
Coccinia Indica ◽  
Trial Drug

The disease Diabetes or Madhumeha is well documented in all perennial sources of Ayurvedic wisdom. The present study was done to evaluate the efficacy of Bimbi (Coccinia indica) in the patients of Diabetes mellitus type-2 through single blind study. Total 30 patients were selected and divided into two groups, 15 patients in each group i.e., A (Bimbi) & B (Barley). In this study it has been found that Madhumeha affects not only in elderly people but in adults too with slight female preponderance. The present study confirmed that after the treatment of 60 days, Bimbi (Coccinia indica) was found effective in treatment of Madhumeha and reduced majority of the symptoms of illness that including Prabootha mootrata (Excessive urination), Atitrushna (Excessive thirst), Avila mootrata (Turbid urine) and Dourbalya (Weakness). There was significant improvement in all the laboratory parameters in patients of Bimbi (Coccinia indica) treated group. The outcome showed that mean reduction in fasting blood sugar level was 19.86%, in PP blood sugar level was 24.52% and in HbA1c level was 8.4%.These outcomes suggest that the results of trial drug i.e., Coccinia indica (Bimbi) powder was highly significant at p-value <0.001. The drug Bimbi showed effectiveness in reducing FBS, PPBS and HbA1c, as results were highly significant. Barley powder used as placebo didn't showed reduction in FBS, PPBS and HbA1c.

scholarly journals Antidiabetic effect of 2-(4- [(2-hydroxyacetyl benzyl) ketoamino]-phenyl amino-methyl)- hydrobenzophenon on Alloxan induced rats

2020 ◽  
Vol 11 (4) ◽  
pp. 7425-7428
Author(s):  
Vurimi Bhopal Chandra ◽  
Kudagi B L ◽  
Madhavulu Buchineni ◽  
Pathapati Rama Mohan ◽  
Anjani Devi Nelavala
Keyword(s):  
Diabetes Mellitus ◽  
Blood Sugar ◽  
Antidiabetic Activity ◽  
Control Group ◽  
Albino Rats ◽  
Average Weight ◽  
Free Access ◽  
High Blood Glucose ◽  
Sugar Levels ◽  
Wistar Albino Rats

Diabetes Mellitus is known as a syndrome, a collection of disorders with high blood glucose level & glucose intolerance as its feature, either because of insulin deficiency or insulin impairment or both. Diabetes Mellitus, based on insulin, is broadly classified into two types. Type one indicates the distraction of pancreatic β - cells that leads to diabetes mellitus, in which insulin is necessary to prevent ketoacidosis, coma, death. Type two diabetes is characterized by disorders of insulin resistance & secretion. Male Wistar albino rats with an average weight of 180-250 g were used in this study. With a 12 hours’ light and dark period, they were kept under normal conditions (room temperature 24-27oC and humidity 60-65 %). The free access of drinking water & pellet diet to male Wistar albino rats was allowed, as per the CPCSEA guidelines. Anti-diabetic activity of Compound 2-(4- [(2-hydroxyacetyl benzyl) ketoamino]-phenyl amino-methyl)- hydrobenzophenon, male Wistar albino rats were divided into four different groups. 1ml of blood samples were collected directly into anticoagulant bottles from the tail vein & later plasma was collected after centrifugation. Blood sugar levels were determined by spectrophotometer. There was a significant decrease in blood sugar levels in Alloxan + Glibenclamide and Alloxan + Compound groups on compared to control. The present self-funded study concludes that antidiabetic activity of 2-(4- [(2-hydroxyacetyl benzyl) ketoamino]-phenyl amino-methyl)- hydrobenzophenon in Alloxan induced diabetic rats significantly shows decreed blood sugar levels when compared to the control group.

scholarly journals Prevalence and clinical features of polycystic ovarian syndrome in adolescents with previous childhood growth hormone deficiency

2016 ◽  
Vol 29 (5) ◽  
Author(s):  
Alessandro Ciresi ◽  
Marco C. Amato ◽  
Jessica Bianco ◽  
Carla Giordano
Keyword(s):  
Growth Hormone ◽  
Polycystic Ovarian Syndrome ◽  
Ovarian Function ◽  
Hdl Cholesterol ◽  
Treated Group ◽  
Hormone Deficiency ◽  
Childhood Growth ◽  
Group A ◽  
Group B ◽  
Ovarian Syndrome

AbstractGrowth hormone (GH) plays a role in the regulation of ovarian function but there are limited data in women with GH deficiency (GHD). Our aim was to evaluate the features of polycystic ovarian syndrome (PCOS) in women with previous GHD.Data of 22 adolescents previously GH-treated (group A) were compared with those of 22 women with classical PCOS (group B) and 20 controls (group C).: Group A showed higher testosterone (p=0.048) and prevalence of menstrual irregularities (p<0.001) than group C. Compared to the group B, group A showed lower diastolic blood pressure (p=0.004), degree of hirsutism (p=0.005), testosterone (p=0.003) and prevalence of polycsytic ovaries (POC) morphology (p=0.024), with higher HDL-cholesterol (p=0.035) and 17-β-estradiol (p=0.009).: Adolescents with previous GHD show a higher prevalence of PCOS than controls, but with milder metabolic and hormonal features than adolescents with classical PCOS. A careful long-term follow-up is advisable in these patients.

scholarly journals SITAGLIPTIN;

2017 ◽  
Vol 24 (11) ◽  
pp. 1755-1760
Author(s):  
Zaheer Ahmed ◽  
Hassan Fareed ◽  
Muhammad Usman Musharraf
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Blood Sugar ◽  
T Test ◽  
P Value ◽  
Diabetic Patients ◽  
Group A ◽  
Group B

The objective of this stidy is to compare the mean reduction of HbA1c in patientstaking sitagliptin insulin combination with insulin alone in patients of type II Diabetes mellitus.Study Design: Randomized control trial (RCT). Setting: Medicine Department, Allied Hospital,Faisalabad. Period: August 2013 to February 2014. Methodology: Patients of both genderswith ages between 18 and 60 years having uncontrolled type 2 diabetes mellitus with HbA1ctaking insulin were included in the study while Pregnant or lactating mothers, patients withchronic liver disease and patients with renal insufficiency (creatinine >3.0mg/dl) were excludedfrom study. Patients were randomly divided into two groups (A &B) using computer generatedrandom number table. Group A was given Sitagliptin 50mg per day and dose was increasedto 100mg per day after 2 weeks if fasting blood sugar was more than 110mg/dl or 2 hourspostprandial blood sugar more than 140mg/dl. Dose of insulin in group A remained same asbefore start of study. Group B was kept on same regimen of insulin they were already taking anddose remained same. HbA1c was done at start of study and after 24 weeks. Primary outcomemeasure was mean reduction in HbA1c levels at 24 weeks from baseline. Results: 60 patientswere included in the study. Mean age was 52.7+8.43 years. 36(60%) were male and 24(40%)were female. Mean HbA1c at baseline was 8.361+0.523% in Group A on Sitagliptin-insulincombination and 8.187+0.432% in group B on insulin alone. Mean HbA1c at 24 weeks was7.767+0.428% in group A on Sitagliptin-insulin combination and 7.69+0.407% in group B oninsulin alone.Independent sample t-test was applied to change in HbA1c in Group A and Bduring 24 weeks of treatment. Mean change in HbA1c after 24 weeks in Group A was 0.600+ 0.315 and 0.49+ 0.19 in Group B after 24 weeks treatment (p-value 0.002) which is highlysignificant. Paired sample t-test was applied to HbA1c at baseline and 24 weeks of treatmentin group A and group B. There was a significant change in both groups after 24 weeks oftreatment in both groups (p-value <0 .000) which is highly significant. Chi Square test wasapplied on efficacy in group A and B. 22(73.33%) patients in group A and 14(46.67%) patientsin group B which achieved significant reduction in HbA1c. 8(26.67%) patients in group A and16(53.33%) patients in group B failed to achieve significant reduction in HbA1c. (P-value <0.032). Conclusion: It has been concluded from this study that insulin and sitagliptin-insulincombination both significantly reduce HbA1c in type 2 diabetes mellitus. However addition ofsitagliptin to uncontrolled diabetic patients already taking insulin, is more effective than insulinfor glycemic control of patients with type 2 diabetes mellitus.

Sign in / Sign up

Export Citation Format

Share Document